Plexxikon Inc.
Plexxikon Announces Preclinical Data Demonstrating Dramatic Improvement in Key Symptoms of Polycystic Kidney Disease
Published in Cancer Weekly, June 10th, 2008
Plexxikon Inc. announced data from preclinical studies of Polycystic Kidney Disease (PKD) demonstrating significantly reduced kidney disease following treatment with Plexxikon's novel drug candidate. Plexxikon's novel small molecule kinase inhibitor is a highly selective and potent inhibitor of Raf kinase, a critical mediator of PKD pathology. These data were recently presented at the ISN Forefronts Symposium on Polycystic Kidney Disease in Montreal, Canada by Stefan Somlo, M.D., CNH Long Professor of Internal Medicine and Genetics and Chief of Nephrology at the Yale University School of Medicine.
"The degree to which this compound slowed progression of the kidney...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-06-10)
More Articles from Cancer Weekly
- Brain Cancer
St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors - Cancer
BiPar Sciences Expands Clinical Development of BSI-201, a Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer - Cancer
Mobile Phones: More Dangerous Than Smoking - Cancer Vaccines
Data on cancer vaccines detailed by M.E. Engelhorn and co-authors - Cancer Vaccines
Recent findings from Mayo Clinic highlight research in cancer vaccines - Cyclacel Pharmaceuticals, Inc.
Vall d'Hebron University Hospital and Cyclacel to Initiate Phase 1 Combination Study of Seliciclib and Tarceva in Advanced Cancers - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
